Johnson & Johnson $JNJ Shares Acquired by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 82,932 shares of the company’s stock after buying an additional 7,108 shares during the period. Farther Finance Advisors LLC’s holdings in Johnson & Johnson were worth $15,377,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in JNJ. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth $27,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at about $48,000. Finally, Vermillion & White Wealth Management Group LLC raised its position in shares of Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.1%

Shares of Johnson & Johnson stock opened at $208.01 on Thursday. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18. The company has a market cap of $501.14 billion, a P/E ratio of 20.08, a PEG ratio of 2.23 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a fifty day moving average of $199.06 and a two-hundred day moving average of $180.31.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: EU approval for Tremfya in pediatric plaque psoriasis expands JNJ’s commercial opportunity in immunology and makes Tremfya the first IL‑23 inhibitor cleared for any pediatric indication — a potential revenue tailwind. JNJ’s Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
• Positive Sentiment: FDA cleared a subcutaneous formulation of Rybrevant for NSCLC, improving patient convenience and potentially broadening uptake versus IV; this strengthens oncology growth prospects. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
• Positive Sentiment: Multiple analyst pieces and model portfolios continue to flag JNJ as a high‑yield, defensive stock for 2026 — supporting demand from income and conservative equity investors. Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026
• Neutral Sentiment: Stifel Nicolaus reiterated a Hold rating on JNJ — a reminder that some analysts remain cautious on near‑term upside despite pipeline progress. Stifel Nicolaus Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Market commentary and earnings previews highlight stronger Q3 results and recent rally/valuation debates — these narratives help explain interest in the stock but don’t change fundamentals immediately. Here’s Why Johnson & Johnson (JNJ) Surged in Q3
• Negative Sentiment: A Baltimore jury ordered J&J to pay roughly $1.5B in a talc/asbestos mesothelioma case — the largest single‑plaintiff talc award reported — creating legal liability risk, potential settlement/appeal costs, and headline volatility. J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award
• Negative Sentiment: Company statements and multiple outlets report the verdict and ongoing exposure (tens of thousands of talc suits), which could weigh on sentiment, raise legal reserves or influence long‑term liability assumptions. Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Wall Street Analyst Weigh In

A number of research analysts recently commented on JNJ shares. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Raymond James Financial boosted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $210.25.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.